The Multifaceted Role of AASDH: From Metabolic Regulation to Cancer and Cardiomyopathies.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-08-01 DOI:10.21873/anticanres.17679

Jaber H Jaradat, Pooya Jalali, Raghad Amro, Hamza K Alsalhi, Ibrahim Serag, Ahmed M Al-Nusairi, Anwaar Saeed

{"title":"The Multifaceted Role of AASDH: From Metabolic Regulation to Cancer and Cardiomyopathies.","authors":"Jaber H Jaradat, Pooya Jalali, Raghad Amro, Hamza K Alsalhi, Ibrahim Serag, Ahmed M Al-Nusairi, Anwaar Saeed","doi":"10.21873/anticanres.17679","DOIUrl":null,"url":null,"abstract":"The enzyme 2-aminoadipic-6-semialdehyde dehydrogenase (AASDH) plays a crucial role in metabolic pathways and has emerged as a significant player in multiple pathological conditions, including cancer and cardiomyopathies. AASDH has been implicated in colorectal cancer (CRC), particularly in microsatellite instability (MSI)-high tumors, in which genetic alterations may contribute to chemotherapy resistance and tumor progression. In addition to CRC, dysregulation of AASDH has been observed in hepatocellular carcinoma (HCC) and lung adenocarcinoma (LUAD), where it influences lipid metabolism and oncogenic pathways. Additionally, emerging evidence suggests a strong link between AASDH and cardiomyopathies, highlighting its potential as a biomarker of ischemic cardiomyopathy-induced heart failure. At the molecular level, AASDH functions in ATP binding and acid-thiol ligase activity, and plays a pivotal role in stress responses, lysine metabolism, and oxidative stress protection. Its association with metabolic reprogramming and the tumor microenvironment suggests that targeting AASDH could enhance current therapeutic strategies for cancer and cardiovascular diseases. This review comprehensively explores the diverse roles of AASDH, emphasizing its potential as a prognostic biomarker and therapeutic target for multiple diseases. A deeper understanding of AASDH may pave the way for novel treatment strategies that integrate metabolic modulation with conventional therapies and improve clinical outcomes in both oncology and cardiology.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3165-3174"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17679","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The enzyme 2-aminoadipic-6-semialdehyde dehydrogenase (AASDH) plays a crucial role in metabolic pathways and has emerged as a significant player in multiple pathological conditions, including cancer and cardiomyopathies. AASDH has been implicated in colorectal cancer (CRC), particularly in microsatellite instability (MSI)-high tumors, in which genetic alterations may contribute to chemotherapy resistance and tumor progression. In addition to CRC, dysregulation of AASDH has been observed in hepatocellular carcinoma (HCC) and lung adenocarcinoma (LUAD), where it influences lipid metabolism and oncogenic pathways. Additionally, emerging evidence suggests a strong link between AASDH and cardiomyopathies, highlighting its potential as a biomarker of ischemic cardiomyopathy-induced heart failure. At the molecular level, AASDH functions in ATP binding and acid-thiol ligase activity, and plays a pivotal role in stress responses, lysine metabolism, and oxidative stress protection. Its association with metabolic reprogramming and the tumor microenvironment suggests that targeting AASDH could enhance current therapeutic strategies for cancer and cardiovascular diseases. This review comprehensively explores the diverse roles of AASDH, emphasizing its potential as a prognostic biomarker and therapeutic target for multiple diseases. A deeper understanding of AASDH may pave the way for novel treatment strategies that integrate metabolic modulation with conventional therapies and improve clinical outcomes in both oncology and cardiology.

查看原文本刊更多论文

AASDH的多方面作用：从代谢调节到癌症和心肌病。

2-氨基己二酸-6-半醛脱氢酶（AASDH）在代谢途径中起着至关重要的作用，并在多种病理条件下发挥重要作用，包括癌症和心肌病。AASDH与结直肠癌（CRC）有关，特别是在微卫星不稳定性（MSI）高的肿瘤中，遗传改变可能导致化疗耐药和肿瘤进展。除结直肠癌外，在肝细胞癌（HCC）和肺腺癌（LUAD）中也观察到AASDH的失调，它影响脂质代谢和致癌途径。此外，新出现的证据表明AASDH与心肌病之间存在密切联系，突出了其作为缺血性心肌病诱发心力衰竭的生物标志物的潜力。在分子水平上，AASDH参与ATP结合和酸-巯基连接酶活性，在应激反应、赖氨酸代谢和氧化应激保护中起关键作用。它与代谢重编程和肿瘤微环境的关联表明，靶向AASDH可以增强当前癌症和心血管疾病的治疗策略。本文全面探讨了AASDH的多种作用，强调了其作为多种疾病的预后生物标志物和治疗靶点的潜力。对AASDH的深入了解可能会为将代谢调节与传统疗法相结合的新治疗策略铺平道路，并改善肿瘤学和心脏病学的临床结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.